The latest financial statement is for the year ending 2025-12-31.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -37,157,151 |
| Amortization | 12,912 |
| Imputed interest | 0 |
| Impairment loss on goodwill | 14,685,271 |
| Impairment loss on intangible assets | 27,619 |
| Issuance of common stock to non-affiliates for services | 22,310,560 |
| Issuance of common stock to related party for services | 10,110 |
| Gain on loan settlement | 16,657 |
| Other receivable | 11,886 |
| Prepaid expense | 10,912 |
| Deferred share issuance cost | 5,000 |
| Accounts payable and accrued liabilities | 72,448 |
| Accrued interest | 13,404 |
| Net cash used in operating activities | -69,282 |
| Net funds from acquisition of xirangsheng (shenzhen) health technology co., ltd | 1,458 |
| Net funds from acquisition of goldfinch-chong (fuzhou) technology co., ltd | 621 |
| Net funds from acquisition of solanai global ltd. hk | 1,281 |
| Net cash provided by investing activities | 3,360 |
| Proceeds from loans | 64,720 |
| Repayment of loans | 5,000 |
| Advancement from related party | 2,013 |
| Proceeds from loan payable - related party | 25,145 |
| Repayment of loan payable - related party | 36,200 |
| Net cash provided by financing activities | 50,678 |
| Effect of exchange rate changes on cash | 2,846 |
| Net change in cash and cash equivalents | -12,398 |
| Cash and cash equivalents, beginning of period | 16,103 |
| Cash and cash equivalents, end of period | 3,705 |